Real life experience with ceftolozane-tazobactam in tertiary hospital

被引：0
|
作者：
Sadyrbaeva-Dolgova, S. [1 ]
Guijarro-Herrera, S. [1 ]
Cancela-Diez, B. [1 ]
Garcia-Fumero, R. [1 ]
Jimenez-Morales, A. [1 ]
机构：
[1] Hosp Univ Virgen Ias Nieves, Granada, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2020年 / 42卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT042
引用
下载
收藏
页码：289 / 290
页数：2
相关论文
共 50 条
  • [31] CEFTOLOZANE-TAZOBACTAM EX VIVO PHARMACOKINETICS IN AN EXTRACORPOREAL MEMBRANE OXYGENATION CIRCUIT
    Cies, Jeffrey
    Moore, Wayne
    Gilliam, Nadju
    Enache, Adela
    Chopra, Arun
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 423 - 423
  • [32] Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains
    Gonzalez, Mark D.
    Wallace, Meghan A.
    Hink, Tiffany
    Dubberke, Erik R.
    Burnham, Carey-Ann D.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (11) : 7084 - 7085
  • [33] CEFTOLOZANE-TAZOBACTAM PHARMACOKINETICS IN A PATIENT ON CONTINUOUS VENO-VENOUS HEMOFILTRATION
    Oliver, Wesley
    Gonzales, Jeffrey
    Heil, Emily
    Mehrotra, Shailly
    Robinett, Kathryn
    Saleeb, Paul
    Nicolau, David
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [34] Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam
    Alosaimy, Sara
    Lagnf, Abdalhamid M.
    Hobbs, Athena L., V
    Mubarez, Musa
    Kufel, Wesley D.
    Morrisette, Taylor
    Polisetty, Radhika S.
    Li, David
    Veve, Michael P.
    Simon, Sam P.
    Truong, James
    Finch, Natalie
    Venugopalan, Veena
    Rico, Matthew
    Amaya, Lee
    Yost, Christine
    Cubillos, Ashley
    Chandler, Elisabeth
    Patch, Megan
    Smith, Ian Murphy Kelsey
    Biagi, Mark
    Wrin, Justin
    Moore, W. Justin
    Molina, Kyle C.
    Rebold, Nicholas
    Holger, Dana
    Coyne, Ashlan J. Kunz
    Jorgensen, Sarah
    Witucki, Paige
    Tran, Nikki N.
    Davis, Susan L.
    Sakoulas, George
    Rybak, Michael J.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1444 - E1455
  • [35] CEFTOLOZANE-TAZOBACTAM ACTIVITY VERSUS RESISTANT PSEUDOMONAS AERUGINOSA FROM PNEUMONIA IN THE US
    Shortridge, Dee
    Streit, Jennifer
    DeRyke, Andrew
    Flamm, Robert
    CRITICAL CARE MEDICINE, 2020, 48
  • [36] Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
    Jolliff, Jeffrey C.
    Ho, Jackie
    Joson, Jeremiah
    Heidari, Arash
    Johnson, Royce
    CASE REPORTS IN INFECTIOUS DISEASES, 2016, 2016
  • [37] Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates
    Snydman, David R.
    McDermott, Laura A.
    Jacobus, Nilda V.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) : 1218 - 1223
  • [38] Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient
    Arena, Fabio
    Marchetti, Luca
    De Angelis, Lucia Henrici
    Maglioni, Enivarco
    Contorni, Martina
    Cassetta, Maria Iris
    Novelli, Andrea
    Rossolini, Gian Maria
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (03)
  • [39] Ceftolozane-tazobactam in nosocomial pneumonia. (vol 35, pg 35, 2022)
    Candel, F. J.
    Gonzalez Del Castillo, J.
    Julian Jimenez, A.
    Matesanz, M.
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 (05) : 508 - 508
  • [40] Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia
    Martin-Loeches, Ignacio
    Bisanti, Alessandra
    Diaz, Emili
    Rodriguez, Alejandro
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (12) : 1177 - 1185
12345